![Birgit Schultes](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 2 M $ al 31/08/2026
Birgit Schultes currently works at Intellia Therapeutics, Inc., as Chief Scientific Officer & Executive VP from 2025.
Dr. Schultes received her graduate degree and doctorate degree from the University of Bonn.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 31/03/2026 | 124.304 ( 0,09 % ) | 2 M $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| INTELLIA THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 13/01/2025 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 2 |
|---|---|
University of Bonn
 University of Bonn Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Intellia Therapeutics, Inc.
 Intellia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel and potentially curative therapeutics | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
